Merck Reduces Workforce at U.S. Plant Due to Decline in Gardasil Demand

Merck & Co. is reducing its workforce at a U.S. facility responsible for producing the HPV vaccine Gardasil, as global demand for the cancer-preventing vaccine declines. Bloomberg posted on X, highlighting the company's decision to adjust its operations in response to shifting market conditions. The reduction in staff reflects a broader trend in the pharmaceutical industry, where companies are adapting to changes in vaccine demand and production needs. Merck's move is part of its strategy to align resources with current market dynamics, ensuring efficiency and sustainability in its operations. The company continues to monitor global demand and adjust its production capabilities accordingly.